From: Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer
Prognostic factor | N | Dead over 5Â years (%) | Hazard ratio (95Â % CI) | p |
---|---|---|---|---|
Model-1 | Â | Â | Â | Â |
CD8 response to Her-2 |  |  | 0.198 (0.05–1.17) | 0.018 |
 Yes | 37 | 11 |  |  |
 No | 33 | 24 |  |  |
Metastasis |  |  | 3.647 (0.89–14.88) | 0.071 |
 No | 32 | 15 |  |  |
 Yes | 42 | 57 |  |  |
pDCs |  |  | 0.292 (0.07–1.17) | 0.083 |
 ≤Median | 36 | 25 |  |  |
 >Median | 34 | 9 |  |  |
Radiotherapy |  |  | 0.107 (0.027–0.41) | 0.001 |
 Yes | 57 | 11 |  |  |
 No | 18 | 44 |  |  |
Chemotherapy |  |  | <0.001 (<0.001–1.67e+130) | 0.941 |
 Yes | 30 | 3 |  |  |
 No | 42 | 31 |  |  |
Model-2 | ||||
CD8 response to Her-2 |  |  | 0.145 (0.02–0.81) | 0.029 |
 Yes | 34 | 12 |  |  |
 No | 28 | 21 |  |  |
pDCs |  |  | 0.093 (0.011–0.809) | 0.031 |
 ≤Median | 31 | 23 |  |  |
 >Median | 31 | 3 |  |  |
Radiotherapy |  |  | 0.091 (0.017–0.492) | 0.005 |
 Yes | 53 | 9 |  |  |
 No | 13 | 38 |  |  |
Chemotherapy |  |  | <0.001 (<0.001–1.9e+157) | 0.949 |
 Yes | 30 | 3 |  |  |
 No | 34 | 26 |  |  |